Related Experiment Video
Updated: Aug 23, 2025

Induction and Micro-CT Imaging of Cerebral Cavernous Malformations in Mouse Model
Published on: September 4, 2017
Dysregulated Hemostasis and Immunothrombosis in Cerebral Cavernous Malformations
Maria Ascencion Globisch1, Favour Chinyere Onyeogaziri1, Ross Osborne Smith1
1Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden.
Cerebral cavernous malformations (CCM) are increasingly viewed as a hemostatic disease. Research highlights the role of blood components and neuroinflammation in CCM development and severity, suggesting new therapeutic avenues.
Area of Science:
- Neuroscience
- Vascular Biology
- Hematology
Background:
- Cerebral cavernous malformation (CCM) affects 0.5% of the population.
- Historically, CCM research focused on genetic mutations and endothelial cell biology.
- Recent studies reveal crucial roles for the hemostatic system and neuroinflammation in CCM.
Purpose of the Study:
- To review the latest molecular insights into CCM pathogenesis.
- To explore the interaction between CCM-deficient endothelial cells, blood components, and the neurovascular unit.
- To underscore the link between endothelial dysfunction and CCM-related symptoms.
Main Methods:
- Comprehensive literature review.
- Analysis of transcriptome and proteome studies.
- Focus on molecular mechanisms and clinical implications.
Main Results:
- Endothelial dysfunction in CCM leads to dysregulated hemostasis.
- Bleeding, hypoxia, and neurological symptoms are linked to endothelial dysfunction.
- CCM is increasingly recognized as a disease involving the hemostatic system.
Conclusions:
- CCM pathogenesis involves complex interactions between endothelial cells and blood components.
- The hemostatic system plays a critical role in CCM development and severity.
- Viewing CCM as a hemostatic disease may open new therapeutic strategies.
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
The Blood-brain Barrier
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care

